The White House added AbbVie’s Humira to its TrumpRx drug discount website at $950 per month. Right next to it: biosimilars from Pfizer and Amgen that cost less.
At $950 on a site built for savings, Humira’s price gets federal validation instead of pressure. That’s not a discount. That’s a menu.
Humira, AbbVie’s megablockbuster, has been one of the world’s best-selling drugs for years. Biosimilars (cheaper copies) are now available in the U.S. The whole point of TrumpRx was supposed to be making drugs affordable — listing the $950 branded version alongside its cheaper alternatives doesn’t accomplish that. It just validates AbbVie’s price point on a government platform.
Getting Humira onto TrumpRx, even at full price, is a win for the company: it legitimizes the product in a program built around affordability. Patients who don’t know better might just choose the name they recognize over a biosimilar they’ve never heard of. The site doesn’t distinguish between them or explain why both are listed.
Pfizer and Amgen’s biosimilars are already listed on the site at lower prices. No one at TrumpRx has explained why the branded version is there too.
Sarah Chen